Uback rankings
How the AI ranks →| Ranking | Tier | Rank | Edition | Next update |
|---|---|---|---|---|
| Telemedicine · worldwide | Top 10 | #8 | Edition 0 (beta) · Sep 2026 | 2 Jan 2027 |
Estimated valuation
AI · Telemedicine ranking (worldwide)- Anchor
- Last known equity round: Series D follow-on · USD 160M (equity and debt) · 2022
- Published valuation
- USD 2bn · Apr 2021 · older than 24 months, shown for reference
An indicative editorial estimate produced by AI, imperfect by nature: neither a financial valuation nor investment advice. Only the market sets a company’s value. Method
Funding history
| Date | Round | Amount | Type | Investors | Source |
|---|---|---|---|---|---|
| 2022 | Series D follow-on | USD 160M (equity and debt) | Equity | Teachers' Venture Growth, P Capital Partners | kry.health |
Rounds as cited by Uback’s rankings and their sources. Equity, debt and grants are shown separately; only equity rounds count towards the valuation anchor.
Independent analyses
By industry professionals & analystsIndustry professionals and financial analysts can publish their own analysis of Kry (Livi) as a PDF, on one of three angles only:
Analyses are the opinion of their authors, not of Uback. They are checked before publication and never change the rank.
Comparable companies in telemedicine
Full telemedicine ranking →Investors in Kry (Livi): Teachers' Venture Growth · P Capital Partners
Sources. kry.health · stockanalysis.com
Last updated: Sep 2026Report an error
Uback is a content publisher. It provides no investment advice, receives no mandate and takes part in no transaction. Rankings, ranges and brackets are editorial estimates produced by AI, purely indicative.